Want to see IRWD full AI Analyst Report?
Total Valuation
Ironwood Pharma has a market cap or net worth of $712.18M. The enterprise value is $1.02K.
Market Cap$712.18M
Enterprise Value$1.02K
Share Statistics
Ironwood Pharma has 165,239,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding165,239,940
Owned by Insiders3.82%
Owned by Institutions20.71%
Financial Efficiency
Ironwood Pharma’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is 11.39%.
Return on Equity (ROE)-0.09
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)11.39%
Return on Capital Employed (ROCE)0.77
Revenue Per Employee2.96M
Profits Per Employee240.17K
Employee Count100
Asset Turnover0.75
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Ironwood Pharma is 5.4. Ironwood Pharma’s PEG ratio is 0.00855.
PE Ratio5.4
PS Ratio1.85
PB Ratio-2.09
Price to Fair Value-2.09
Price to FCF4.30
Price to Operating Cash Flow3.89
PEG Ratio0.00855
Income Statement
In the last 12 months, Ironwood Pharma had revenue of 296.15M and earned 24.02M in profits. Earnings per share was 0.15.
Revenue296.15M
Gross Profit296.15M
Operating Income118.76M
Pretax Income70.03M
Net Income24.02M
EBITDA104.65M
Earnings Per Share (EPS)0.15
Cash Flow
In the last 12 months, operating cash flow was 185.56M and capital expenditures -1.00K, giving a free cash flow of 185.55M billion.
Operating Cash Flow185.56M
Free Cash Flow185.55M
Free Cash Flow per Share1.12
Dividends & Yields
Ironwood Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change285.84%
50-Day Moving Average3.99
200-Day Moving Average3.80
Relative Strength Index (RSI)56.12
Average Volume (3m)2.34M
Important Dates
Ironwood Pharma upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Ironwood Pharma as a current ratio of 1.13, with Debt / Equity ratio of -245.22%
Current Ratio1.13
Quick Ratio1.13
Debt to Market Cap1.07
Net Debt to EBITDA3.65
Interest Coverage Ratio3.63
Taxes
In the past 12 months, Ironwood Pharma has paid 46.01M in taxes.
Income Tax46.01M
Effective Tax Rate0.66
Enterprise Valuation
Ironwood Pharma EV to EBITDA ratio is 8.88, with an EV/FCF ratio of 7.31.
EV to Sales3.14
EV to EBITDA8.88
EV to Free Cash Flow7.31
EV to Operating Cash Flow7.31
Balance Sheet
Ironwood Pharma has $79.13M in cash and marketable securities with $396.87M in debt, giving a net cash position of -$317.74M billion.
Cash & Marketable Securities$79.13M
Total Debt$396.87M
Net Cash-$317.74M
Net Cash Per Share-$1.92
Tangible Book Value Per Share-$1.63
Margins
Gross margin is 99.76%, with operating margin of 40.10%, and net profit margin of 8.11%.
Gross Margin99.76%
Operating Margin40.10%
Pretax Margin23.65%
Net Profit Margin8.11%
EBITDA Margin35.34%
EBIT Margin34.70%
Analyst Forecast
The average price target for Ironwood Pharma is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast26.19%
EPS Growth Forecast―